Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624171 | 0.84 | CTSK (0.47) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL4367383 | 0.77 | CTSK (0.51) | CTSKKMT2AALDH1A1MAPT | |
| SCHEMBL13624325 | 0.76 | CTSK (0.49) | CTSKKMT2ACTSLALDH1A1MAPT | |
| SCHEMBL4368196 | 0.71 | CTSK (0.42) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL2156068 | 0.70 | CTSK (0.66) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624184 | 0.70 | CTSL (0.42) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL13624280 | 0.70 | CTSB (0.40) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624389 | 0.67 | CTSK (0.50) | CTSKKMT2ACTSLALDH1A1MAPT | |
| SCHEMBL13624278 | 0.66 | CTSB (0.57) | CTSKCTSLCTSSCTSB | |
| SCHEMBL13624309 | 0.66 | CTSL (0.58) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSK 15/4885KMT2A 3986/4885CTSL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.